Proton pump inhibitors and gastric neoplasia

Gut

Volumn 55, Issue 9, 2006, Pages 1217-1221

  Kuipers, E J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ACID SECRETION; ATROPHIC GASTRITIS; BACTERIAL COLONIZATION; CANCER DIAGNOSIS; CANCER RISK; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REMISSION; REVIEW; STOMACH CANCER; STOMACH CARCINOID; STOMACH FUNCTION; STOMACH FUNDOPLICATION; STOMACH FUNDUS; STOMACH MUCOSA; STOMACH POLYP; STOMACH TUMOR;

ANTI-ULCER AGENTS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMPS; STOMACH NEOPLASMS;

EID: 33747770334     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.090514     Document Type: Review

References (45)

1. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91
2. van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005;54:1062-6.
3. van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006 (in press).
4. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129:1171-8.
5. Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42(suppl 3):iii23-31.
6. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer, but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006;23:1587-93.
7. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:605-12.
8. Larsson H, Carlsson E, Hakanson R, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988;95:1477-86.
9. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
10. Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000;31:684-90.
11. Jalving M, Koornstra JJ, Boersma-van Ek W, et al. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol 2003;38:916-22.
12. Watanabe N, Seno M, Nakajima T, et al. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut 2002;51:742-5.
13. Jalving M, Koornstra JJ, Gotz JM, et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 2003;15:1229-33.
14. Wu TT, Kornacki S, Rashid A, et al. Dysplasia and deregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 1998;22:293-8.
15. Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol 2002;97:298-301.
16. Verdú E, Armstrong D, Fraser R, et al. Effect of H. pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
17. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-16.
18. Kuipers EJ, Lee A, Klinkenberg-Knol EC, et al. Review article: The development of atrophic gastritis-Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther 1995;9:331-40.
19. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Efficacy and safety of long-term treatment with omeprazole for refractory reflux esophagitis. Ann Intern Med 1994;121:161-7.
20. Solcia E, Fiocca R, Havu N, et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992;51:82-92.
21. Lamberts R, Creutzfeldt W, Strüber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:1356-70.
22. Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 1991;26:90-4.
23. Peetsalu A, Maaroos HI, Sipponen P, et al. Long-term effect of vagotomy on gastric mucosa and Helicobacter pylori in duodenal ulcer patients. Scand J Gastroenterol 1991;26:77-83.
24. Brunner GHG, Lamberts R, Creutzfeldt W. Efficacy and safety of omeprazole in long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990;47:64-8.
25. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
26. Lundell L, Havu N, Miettinen P, et al. No effect of acid suppression therapy over five years on gastric glandular atrophy. Results of a randomised clinical study. Gastroenterology 1999;118:A214.
27. McColl KEL, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:239.
28. Pounder RE, Williams MP. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:238-9.
29. Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SGM. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:239-40.
30. Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006;23:639-47.
31. Eissele R, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobader pylori is a risk factor for argyrophil-cell hyperplasia. Gastroenterology 1997;112:707-17.
32. Geboes K, Dekker W, Mulder Q, et al. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001;15:1819-26.
33. Marzio L, Biasco G, Cifani F, et al. Short- and long-term omeprazole for the treatment and prevention of duodenal ulcer, and effect on Helicobacter pylori. Am J Gastroenterol 1995;90:2172-6.
34. Stolte M, Meining A, Schmitz JM, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:247-53.
35. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther 1999;13:1343-6.
36. Sanduleanu S, Jonkers D, De Bruine A, et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 2001;15:1163-75.
37. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
38. Hansen S, Vollset SE, Ardill JES, et al. Hypergastrinemia is a strong predictor of distal gastric adenocarcinoma among Helicobacter pylori infected persons. Gut 1997;41:A41.
39. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report 2005. Submitted, 2006.
40. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-14.
41. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease; results of a randomised controlled trial. Gut 2004;53:12-20.
42. Panter SJ, O'Flanagan H, Bramble MG, et al. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment Pharmacol Ther 2004;19:981-8.
43. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000;46:464-7.
44. Lassen A, Hallas J, de Muckadell OB. The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication. Gastroenterology 2005;129:1179-86.
45. Wayman J, Hayes N, Raimes SA, et al. Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000:385-8.